We next investigated the effects of several AhR-active pharmaceuticals including leflunomide (Figure 1B), mexiletine (Figure 1C), tranilast (Figure 1D), β-naphthoflavone (Figure 1E), the AhR active microbial metabolite tryptamine (Figure 1F), and OME, a pharmaceutical that inhibits invasion of breast and pancreatic cancer cells [44,45] (Figure 1G). This evidence concerns the gene AHR and familial pancreatic carcinoma.